Faculty Opinions recommendation of Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasat... D Krause - Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature 被引量: 0发表: 2021年 End-of-life issues in ...
Novartis Pharmaceuticals Corporation30 September 2024 ARZERRA (Ofatumumab) Chronic Lymphocytic Leukemia (CLL). ARZERRA (ofatumumab) is indicated: in combination with chlorambucil, for the treatment of previously untreated patients with CLL for whom… Novartis Pharmaceuticals Corporation26 June 20241...
AstraZeneca Pharmaceuticals LP; Bayer, Bayer HealthCare Pharmaceuticals Inc.; Bryant, Bryant Ranch Prepack; Celgene, Celgene Corporation; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CTCL, cutaneous T-cell lymphoma; DCIS, ductal carcinoma insitu; EGFR, epidermal growth factor; E...
Multiple sclerosis (MS) is a chronic autoimmune inflammatory disorder of the central nervous system (CNS) that can lead to neurological defects and severe incapacitation [1]. With a global prevalence of 2.8 million, it is the most common debilitating neurological disease among young adults, with...
During the screening portion of the survey, panel members’ chronic disease status was reconfirmed and their medication-taking behavior for the index condition was solicited. The screener solicited the number of medications respondents currently took for each disease as well as the length of time the...
The evolution of dasatinib dosage over the years and its relevance to other anticancer medications.A lower dose of 50 mg of dasatinib is effective when used as the initial treatment of patients with chronic﹑hase chronic myeloid leukemia... Schiffer,Charles A - 《Cancer》 被引量: 3发表: 2018...
For instance, one study found that patients with chronic myeloid leukemia with >90% adherence to imatinib demonstrated increased probability of a six-year 3-log reduction of disease compared to patients with adherence levels ≤90% (94.5% vs. 28.4%, p < 0.001) [28]. Consequences of non-...
These pathways involve different sets of gene dysregulations related to similar signaling pathways, including Wnt, KRAS, SMAD mutations for CIN tumors, β-catenins, PIK3CA/PTEN, and TGFβ-R2 for MSI tumors. Chronic diseases, including intestinal inflammation, are also associated with an increased ...